Factor VIII inhibitors: Role of von Willebrand factor on the uptake of factor VIII by dendritic cells

Haemophilia

Volumn 13, Issue SUPPL. 5, 2007, Pages 61-64

  Kaveri, Srinivas V ^a,b,c   Dasgupta, S ^a,b,c   Andre, S ^a,b,c   Navarrete, A M ^a,b,c   Repesse Y ^a,b,c   Wootla, B ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Factor VIII; Haemophilia A; Inhibitors; Replacement therapy; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; PROTHROMBIN COMPLEX; VON WILLEBRAND FACTOR;

ALLOIMMUNIZATION; ANAMNESIS; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DRUG MEGADOSE; DRUG UPTAKE; ENDOCYTOSIS; GENETIC RISK; HEMOPHILIA A; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INTERNALIZATION; PRIORITY JOURNAL; RISK FACTOR;

ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; COAGULANTS; DENDRITIC CELLS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; VON WILLEBRAND FACTOR;

EID: 37149017979     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01575.x     Document Type: Article

References (29)

1. White GC II, Shoemaker CB. Factor VIII gene and hemophilia A. Blood 1989; 73: 1-12.
2. Astermark J. Why do inhibitors develop?. Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12 (Suppl. 3): 52-60.
3. Lenting PJ, Van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
4. Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-9.
5. Figueiredo MS, Brownlee GG. cis-acting elements and transcription factors involved in the promoter activity of the human factor VIII gene. J Biol Chem 1995; 270: 11828-38.
6. Kadhom N, Wolfrom C, Gautier M, Allain JP, Frommel D. Factor VIII procoagulant antigen in human tissues. Thromb Haemost 1988; 59: 289-94.
7. Stel HV, Van der Kwast TH, Veerman EC. Detection of factor VIII/ coagulant antigen in human liver tissue. Nature 1983; 303: 530-2.
8. Van der Kwast TH, Stel HV, Cristen E, Bertina RM, Veerman EC. Localization of factor VIII-procoagulant antigen: An immunohistological survey of the human body using monoclonal antibodies. Blood 1986; 67: 222-7.
9. Zelechowska MG, Van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 1985; 317: 729-30.
10. Lollar P. The association of factor VIII with von Willebrand factor. Mayo Clin Proc 1991; 66: 524-34.
11. Fay PJ, Coumans J-V, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-7.
12. Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 1990; 265: 17854-8.
13. Lollar P, Knutson GJ, Fass DN. Activation of porcine factor VIII:C by thrombin and factor Xa. Biochemistry 1985; 24: 8056-64.
14. Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem 1996; 271: 11120-5.
15. Astermark J. Overview of inhibitors. Semin Hematol 2006; 43 (Suppl. 4): S3-7.
16. Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies: Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 78-84.
17. Foster PA, Fulcher CA, Huoghten RA, De Graaf Mahoney S, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-FVIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine 351 -serine 365 of the factor VIII heavy chain. J Clin Invest 1988; 82: 123-8.
18. Lubahn BC, Ware J, Stafford DW, Reisner HM. Identification of a FVIII epitope recognized by a human hemophilic inhibitor. Blood 1989; 73: 497-9.
19. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for FVIII inhibition. J Biol Chem 1996; 271: 27424-31.
20. Shima M, Scandella D, Yoshioka A et.al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-6.
21. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92: 136-42.
22. Lacroix-Desmazes S, Bayry J, Misra N et.al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 2002; 346: 662-7.
23. Lacroix-Desmazes S, Moreau A, Sooryanarayana V et.al. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat Med 1999; 5: 1044-7.
24. Lacroix-Desmazes S, Wootla B, Dasgupta S et.al. Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII. J Immunol 2006; 177: 1355-63.
25. Misra N, Bayry J, Pashov A et.al. Restricted BV gene usage by factor VIII-reactive CD4+ T cells in inhibitor-positive patients with severe hemophilia A. Thromb Haemost 2003; 90: 813-22.
26. Jacquemin M, Vantomme V, Buhot C et.al. CD4+ T-cell clones specific for wild-type factor VIII: A molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
27. Reding MT, Wu H, Krampf M et.al. CD4+ T cells specific for factor VIII as a target for specific suppression of inhibitor production. Adv Exp Med Biol 2001; 489: 119-34.
28. Kreuz W, Ettingshausen CE, Auerswald G et.al. Epidemiology of inhibitors and current treatment strategies. Haematologica 2003; 88: EREP04.
29. Dasgupta S, Repesse Y, Bayry J et.al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2.